|Bid||263.92 x 13700|
|Ask||263.95 x 21700|
|Day's range||263.95 - 267.51|
|52-week range||242.00 - 322.75|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||34.91|
|Earnings date||18 Feb 2021|
|Forward dividend & yield||2.70 (1.01%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||151.95|
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed medical journal Clinical Infectious Diseases.1 Study results indicate aTIV was more effective in reducing influenza-related medical encounters compared with standard egg-based quadrivalent influenza vaccine (QIVe) and high-dose trivalent influenza vaccine (TIV-HD) among adults 65 years and older during the 2017/18 and 2018/19 U.S. influenza seasons.1
Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...